Usefulness of N- Terminal pro-B- Type natriuretic peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation

Stroke

Volumn 45, Issue 3, 2014, Pages 696-701

  Roldán, Vanessa ^a   Vílchez, Juan Antonio ^a   Manzano Fernández, Sergio ^a   Jover, Eva ^a   Gálvez, Josefa ^a   Puche, Carmen M ^a   Valdés, Mariano ^a   Vicente, Vicente ^a   Lip, Gregory Y H ^b   Marín, Francisco ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Anticoagulants; Atrial fibrillation; B Type natriuretic peptide; Stroke

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTICOAGULANT AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE HEART FAILURE; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RISK FACTOR; SEX DIFFERENCE; B-TYPE NATRIURETIC PEPTIDE; BIOASSAY; BLOOD; CARDIOVASCULAR DISEASE; REGRESSION ANALYSIS; RISK ASSESSMENT; VERY ELDERLY;

ANTICOAGULANTS; ATRIAL FIBRILLATION; B-TYPE NATRIURETIC PEPTIDE; STROKE;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; COHORT STUDIES; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERNATIONAL NORMALIZED RATIO; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS; STROKE;

EID: 84899134326     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.113.003338     Document Type: Article

References (30)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991;22:983-988.
2. Hart RG, Pearce LA, Aguilar MI. Meta- Analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-867.
3. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. J Am Med Assoc. 2001;285:2864-2870.
4. Keogh C, Wallace E, Dillon C, Dimitrov BD, Fahey T. Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta- Analysis. Thromb Haemost. 2011;106:528-538.
5. Lip GY, Nieuwlaat R, Pisters R, Lane D, Crijns H. Refining clinical risk stratification for predicting stroke in atrial fibrillation using a novel risk factor based approach: The Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137:263-272.
6. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, et al; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719-2747.
7. Lip GY. Stroke and bleeding risk assessment in atrial fibrillation: when, how, and why? Eur Heart J. 2013;34:1041-1049.
8. Jover E, RoldSn V, Gallego P, Hemández-Romero D, Valdés M, Vicente V, et al. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation. Rev Esp Cardiol (Engl Ed). 2012;65:627-633.
9. Hijazi Z, Oldgren J, Siegbahn A, Granger CB, Wallentin L. Biomarkers in atrial fibrillation: Aclinical review. Eur Heart J. 2013;34:1475-1480.
10. Hijazi Z, Oldgren J, Andersson U, Connolly SJ, Ezekowitz MD, Hohnloser SH, et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: A Randomized Evaluation of Long- Term Anticoagulation Therapy (RE-LY) substudy. Circulation. 2012;125:1605-1616.
11. Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, Ezekowitz J, et al. N- Terminal pro-B- Type natriuretic peptide for risk assessment in patients with atrial fibrillation: Insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol. 2013;61:2274-2284.
12. Rolddn V, Marin F, Muifia B, Torregrosa JM, Herndndez-Romero D, Valdds M, et al. Plasma von Willebrand factor levels are an independent risk factor for adverse events including mortality and major bleeding in anticoagulated atrial fibrillation patients. J Am Coll Cardiol. 2011;57: 2496-2504.
13. Boomsma F, van den Meiracker AH. Plasma A- And B- Type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res. 2001;51:442-449.
14. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, et al. N- Terminal pro-B- Type natriuretic peptide is a major predictor of the development of atrial fibrillation: The Cardiovascular Health Study. Circulation. 2009;120:1768-1774.
15. Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The Euro Heart Survey. Chest. 2010;138:1093-1100.
16. Schulman S, Anger&s U, Bergqvist D, Eriksson B, Lassen MR, Fisher W; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in suigical patients. J Thromb Haemost. 2010;8:202-204.
17. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-207.
18. Di Angelantonio E, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, et al. B- Type natriuretic peptides and cardiovascular risk: systematic review and meta- Analysis of 40 prospective studies. Circulation. 2009; 120: 2177-2187.
19. Asanin M, Stankovic S, Mrdovic I, Matic D, Savic L, Majkic-Singh N, et al. B- Type natriuretic peptide predicts new-onset atrial fibrillation in patients with ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention. Peptides. 2012;35:74-77.
20. Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, et al. N- Terminal pro-B- Type natriuretic peptide is a major predictor of the development of atrial fibrillation: The Cardiovascular Health Study. Circulation. 2009;120:1768-1774.
21. Montaner J, Perea-Gainza M, Delgado P, Ribó M, Chacón P, Rosell A, et al. Etiologic diagnosis of ischemic stroke subtypes with plasma biomarkers. Stroke. 2008;39:2280-2287.
22. Shibazaki K, Kimura K, Iguchi Y, Okada Y, Inoue T. Plasma brain natriuretic peptide can be a biological marker to distinguish cardioembolic stroke from other stroke types in acute ischemic stroke. Intern Med. 2009;48:259-264.
23. Shibazaki K, Kimura K, Fujii S, Sakai K, Iguchi Y. Brain natriuretic peptide levels as a predictor for new atrial fibrillation during hospitalization in patients with acute ischemic stroke. Am J Cardiol. 2012;109:1303-1307.
24. Goetze JP, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of B- Type natriuretic peptide. Eur Heart J. 2006;27:1648-1650.
25. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail. 2000;6:92-96.
26. Shimizu H, Murakami Y, Inoue S, Ohta Y, Nakamura K, Katoh H, et al. High plasma brain natriuretic polypeptide level as a marker of risk for thromboembolism in patients with nonvalvular atrial fibrillation. Stroke. 2002;33:1005-1010.
27. Tamura H, Watanabe T, Nishiyama S, Sasaki S, Wanezaki M, Arimoto T, et al. Elevated plasma brain natriuretic peptide levels predict left atrial appendage dysfunction in patients with acute ischemic stroke. J Cardiol. 2012;60:126-132.
28. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998;82(suppl):2N-9N.
29. Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, et al; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(suppl 6):546S-592S.
30. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr. Plasma brain natriuretic peptide concentration: Impact of age and gender. J Am Coll Cardiol. 2002;40:976-982.